{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:58:43Z","timestamp":1773831523926,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:00:00Z","timestamp":1712448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:00:00Z","timestamp":1712448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norwegian Research Council","doi-asserted-by":"crossref","award":["the DoMore Project (259204)"],"award-info":[{"award-number":["the DoMore Project (259204)"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005416","name":"Norwegian Research Council","doi-asserted-by":"crossref","award":["the Bench to Bedside Project (309610)"],"award-info":[{"award-number":["the Bench to Bedside Project (309610)"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40273-024-01371-1","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T19:01:37Z","timestamp":1712516497000},"page":"679-691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?"],"prefix":"10.1007","volume":"42","author":[{"given":"Anna","family":"Kenseth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominika","family":"Kantorova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4746-2264","authenticated-orcid":false,"given":"Mikyung Kelly","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eline","family":"Aas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"Askautrud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rn Evert","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,7]]},"reference":[{"key":"1371_CR1","unstructured":"GlobalData. Colorectal Cancer: Epidemiology Forecast to 2028. 2019. Contract No.: GDHCER220-19."},{"key":"1371_CR2","unstructured":"Norway CRo. Cancer in Norway 2018\u2014Cancer incidence, mortality, survival and prevalence in Norway. Oslo; 2019. Report No.: 0806-3621."},{"key":"1371_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.4_suppl.587","author":"H Crooke","year":"2018","unstructured":"Crooke H, Kobayashi M, Mitchell B, Nwokeji E, Laurie M, Kamble S, et al. Estimating 1-and 5-year relative survival trends in colorectal cancer (CRC) in the United States: 2004 to 2014. J Clin Oncol. 2018. https:\/\/doi.org\/10.1200\/JCO.2018.36.4_suppl.587.","journal-title":"J Clin Oncol"},{"key":"1371_CR4","volume-title":"AJCC cancer staging manual","author":"SB Edge","year":"2010","unstructured":"Edge SB, Byrd DR, Carducci MA, Compton CC, Fritz A, Greene F. AJCC cancer staging manual. New York: Springer; 2010."},{"issue":"9","key":"1371_CR5","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1097\/DCR.0000000000001158","volume":"61","author":"E Osterman","year":"2018","unstructured":"Osterman E, Glimelius B. Recurrence risk after up-to-date colon cancer staging, surgery, and pathology: analysis of the entire Swedish population. Dis Colon Rectum. 2018;61(9):1016\u201325.","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"1371_CR6","first-page":"127","volume":"69","author":"WL Bi","year":"2019","unstructured":"Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, et al. Artificial intelligence in cancer imaging: clinical challenges and applications. CA: Cancer J Clin. 2019;69(2):127\u201357.","journal-title":"CA: Cancer J Clin"},{"issue":"1","key":"1371_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-336","volume":"14","author":"VL Tsikitis","year":"2014","unstructured":"Tsikitis VL, Larson DW, Huebner M, Lohse CM, Thompson PA. Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer. 2014;14(1):1\u20137.","journal-title":"BMC Cancer"},{"issue":"1","key":"1371_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/ijms18010107","volume":"18","author":"A Copija","year":"2017","unstructured":"Copija A, Waniczek D, Witko\u015b A, Walkiewicz K, Nowakowska-Zajdel E. Clinical significance and prognostic relevance of microsatellite instability in sporadic colorectal cancer patients. Int J Mol Sci. 2017;18(1):107.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1371_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181970","volume":"12","author":"H Lyu","year":"2017","unstructured":"Lyu H, Xu T, Brotman D, Mayer-Blackwell B, Cooper M, Daniel M, et al. Overtreatment in the united states. PLoS ONE. 2017;12(9): e0181970.","journal-title":"PLoS ONE"},{"issue":"7","key":"1371_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1002\/pon.5054","volume":"28","author":"A Shrestha","year":"2019","unstructured":"Shrestha A, Martin C, Burton M, Walters S, Collins K, Wyld L. Quality of life versus length of life considerations in cancer patients: a systematic literature review. Psychooncology. 2019;28(7):1367\u201380.","journal-title":"Psychooncology"},{"key":"1371_CR11","unstructured":"Group F-NBW. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. 2016."},{"issue":"3","key":"1371_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(3):329\u201359.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"1371_CR13","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argil\u00e9s","year":"2020","unstructured":"Argil\u00e9s G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291\u2013305.","journal-title":"Ann Oncol"},{"key":"1371_CR14","unstructured":"Team O. The Oncotype\u00ae DX Breast Recurrence Score."},{"issue":"28","key":"1371_CR15","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","volume":"29","author":"G Yothers","year":"2011","unstructured":"Yothers G, O\u2019Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768.","journal-title":"J Clin Oncol"},{"issue":"10221","key":"1371_CR16","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0140-6736(19)32998-8","volume":"395","author":"OJ Skrede","year":"2020","unstructured":"Skrede OJ, De Raedt S, Kleppe A, Hveem TS, Liest\u00f8l K, Maddison J, et al. Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. Lancet. 2020;395(10221):350\u201360.","journal-title":"Lancet"},{"issue":"4","key":"1371_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","volume":"24","author":"Z Philips","year":"2006","unstructured":"Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment. Pharmacoeconomics. 2006;24(4):355\u201371.","journal-title":"Pharmacoeconomics"},{"key":"1371_CR18","unstructured":"Guidelines for the submission of documentation for single technology assessments (STAs) of medical devices and diagnostic interventions. In: Health NIoP, editor. 2020."},{"key":"1371_CR19","doi-asserted-by":"crossref","unstructured":"Seo MK, Strong M. A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper. PharmacoEconomics. 2021;1\u20139.","DOI":"10.1007\/s40273-021-01069-8"},{"key":"1371_CR20","first-page":"1","volume":"21","author":"L Yang","year":"2023","unstructured":"Yang L, Yang J, Kleppe A, Danielsen HE, Kerr DJ. Personalizing adjuvant therapy for patients with colorectal cancer. Nat Rev Clin Oncol. 2023;21:1\u201313.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"1371_CR21","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S1470-2045(16)30172-3","volume":"17","author":"RS Kerr","year":"2016","unstructured":"Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, et al. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncol. 2016;17(11):1543\u201357.","journal-title":"Lancet Oncol"},{"key":"1371_CR22","doi-asserted-by":"crossref","unstructured":"Latimer NR. Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data [Internet]. 2013.","DOI":"10.1177\/0272989X12472398"},{"issue":"2","key":"1371_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/0272989X14544749","volume":"35","author":"P Joranger","year":"2015","unstructured":"Joranger P, Nesbakken A, Hoff G, Sorbye H, Oshaug A, Aas E. Modeling and validating the cost and clinical pathway of colorectal cancer. Med Decis Making. 2015;35(2):255\u201365.","journal-title":"Med Decis Making"},{"key":"1371_CR24","unstructured":"StatBank. Statistics Norway Mortality Tables. 2019. https:\/\/www.ssb.no\/en\/statbank\/table\/07902."},{"key":"1371_CR25","unstructured":"Felleskatalogen [The Norwegian Medicines Catalog]: Felleskatalog [The Norwegian Medicines Catalog]; 2020: https:\/\/www.felleskatalogen.no\/medisin."},{"key":"1371_CR26","unstructured":"DCTD N, NIH, DHHS. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 2006."},{"key":"1371_CR27","unstructured":"Capecitabine Accord Felleskatalog2020: https:\/\/www.felleskatalogen.no\/medisin\/capecitabine-accord-accord-586441."},{"key":"1371_CR28","unstructured":"Oxaliplatin Fresenius Kabi Felleskatalog2019: https:\/\/www.felleskatalogen.no\/medisin\/oxaliplatin-fresenius-kabi-fresenius-kabi-568997."},{"key":"1371_CR29","unstructured":"DRG-systemet [DRG-system]. In: Health] HNDo, editor. Oslo: Helsedirektoratet; 2020."},{"issue":"3","key":"1371_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10198-019-01130-6","volume":"21","author":"P Joranger","year":"2020","unstructured":"Joranger P, Nesbakken A, Sorbye H, Hoff G, Oshaug A, Aas E. Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. Eur J Health Econ. 2020;21(3):321\u201334.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"1371_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12913-019-4794-6","volume":"20","author":"GMW Bj\u00f8rnelv","year":"2020","unstructured":"Bj\u00f8rnelv GMW, Edwin B, Fretland \u00c5A, Deb P, Aas E. Till death do us part: the effect of marital status on health care utilization and costs at end-of-life. A register study on all colorectal cancer decedents in Norway between 2009 and 2013. BMC Health Serv Res. 2020;20(1):115.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"1371_CR32","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1294::AID-CNCR4>3.0.CO;2-M","volume":"88","author":"SD Ramsey","year":"2000","unstructured":"Ramsey SD, Andersen MR, Etzioni R, Moinpour C, Peacock S, Potosky A, Urban N. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88(6):1294\u2013303.","journal-title":"Cancer"},{"issue":"2","key":"1371_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0272989X9301300202","volume":"13","author":"DG Fryback","year":"1993","unstructured":"Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, Martin PA. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89\u2013102.","journal-title":"Med Decis Making"},{"key":"1371_CR34","unstructured":"Magnussen J, Aaserud M, Granaas T, Magelssen M, Syse A, Celius E. P\u00e5 ramme alvor-Alvorlighet og prioritering. Department of Health (p. 71). English summary available from: https:\/\/www.regjeringen.no\/contentassets\/d5da48ca5d1a4b128c72fc5daa3b4fd8\/summary_the_magnussen_report_on_severity.pdf. 2015."},{"issue":"2","key":"1371_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hec.4730030206","volume":"3","author":"A Briggs","year":"1994","unstructured":"Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994;3(2):95\u2013104.","journal-title":"Health Econ"},{"issue":"8","key":"1371_CR36","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jval.2012.07.012","volume":"15","author":"J Hornberger","year":"2012","unstructured":"Hornberger J, Lyman GH, Chien R, Meropol NJ. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. Value in Health. 2012;15(8):1014\u201321.","journal-title":"Value in Health."},{"key":"1371_CR37","doi-asserted-by":"publisher","first-page":"175628482199571","DOI":"10.1177\/1756284821995715","volume":"14","author":"G Jongeneel","year":"2021","unstructured":"Jongeneel G, Greuter MJ, van Erning FN, Koopman M, Vink GR, Punt CJ, Coup\u00e9 VM. Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients. Ther Adv Gastroenterol. 2021;14:1756284821995715.","journal-title":"Ther Adv Gastroenterol"},{"key":"1371_CR38","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s40273-014-0207-1","volume":"32","author":"SR Alberts","year":"2014","unstructured":"Alberts SR, Yu TM, Behrens RJ, Renfro LA, Srivastava G, Soori GS, et al. Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer. Pharmacoeconomics. 2014;32:1231\u201343.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"1371_CR39","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s40273-021-01047-0","volume":"39","author":"YH To","year":"2021","unstructured":"To YH, Degeling K, Kosmider S, Wong R, Lee M, Dunn C, et al. Circulating tumour DNA as a potential cost-effective biomarker to reduce adjuvant chemotherapy overtreatment in stage II colorectal cancer. Pharmacoeconomics. 2021;39(8):953\u201364.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1371_CR40","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jval.2021.07.019","volume":"25","author":"F Alarid-Escudero","year":"2022","unstructured":"Alarid-Escudero F, Schrag D, Kuntz KM. CDX2 biomarker testing and adjuvant therapy for stage II colon cancer: an exploratory cost-effectiveness analysis. Value in Health. 2022;25(3):409\u201318.","journal-title":"Value in Health."},{"issue":"9","key":"1371_CR41","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S1470-2045(22)00391-6","volume":"23","author":"A Kleppe","year":"2022","unstructured":"Kleppe A, Skrede O-J, De Raedt S, Hveem TS, Askautrud HA, Jacobsen JE, et al. A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study. Lancet Oncol. 2022;23(9):1221\u201332.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1371_CR42","first-page":"iii","volume":"8","author":"L Jones","year":"2004","unstructured":"Jones L, Hawkins N, Westwood M, Wright K, Richardson G, Riemsma R. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and\/or metastatic breast cancer. Health Technol Assess (Winchester, England). 2004;8(5):iii\u2013143.","journal-title":"Health Technol Assess (Winchester, England)."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01371-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01371-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01371-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T15:25:42Z","timestamp":1716564342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01371-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,7]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1371"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01371-1","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,7]]},"assertion":[{"value":"3 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by the Norwegian Research Council through the DoMore Project (259204) and the Bench to Bedside Project (309610).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AK, DK, HA, and JEJ report having stocks in DoMore Diagnostics. All other authors declare no competing interests. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All necessary data and information are provided in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors consent to participate.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consent for publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Study concept and design: AK, DK, MKS, EA, JEJ. Data analysis: AK, DK, MKS. Model development: AK, DK, MKS. Manuscript writing, original draft: AK, DK. Manuscript review and editing: AK, DK, MKS, EA, JC, DK, HA, JEJ. Supervision: MKS","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}